Top

Current Reviews in Musculoskeletal Medicine

Published in:

01-09-2018 | Prosthetic Joint Infection (S Nodzo and N Frisch, section editors)

New Innovations in the Treatment of PJI and Biofilms—Clinical and Preclinical Topics

Authors: Mariam Taha, Hesham Abdelbary, F. Patrick Ross, Alberto V. Carli

Published in: Current Reviews in Musculoskeletal Medicine | Issue 3/2018

Abstract

Purpose of Review

Periprosthetic joint infection (PJI) is a devastating complication after total joint replacement. A main source for antibiotic tolerance and treatment failure is bacterial production of biofilm—a resilient barrier against antibiotics, immune system, and mechanical debridement. The purpose of this review is to explore some novel approaches to treat PJI and biofilm-related infections.

Recent Findings

Innovative treatment strategies of bacterial and biofilm infections revolve around (a) augmenting current therapies, such as improving the delivery and efficiency of conventional antibiotics and enhancing the efficacy of antiseptics and (b) administrating completely new therapeutic modalities, such as using immunotherapy, nanoparticles, lytic bacteriophages, photodynamic therapy, novel antibiotics, and antimicrobial peptides.

Summary

Several promising treatment strategies for PJI are available to be tested further. The next requirement for most of the novel treatments is reproducing their effects in clinically representative animal models of PJI against clinical isolates of relevant bacteria.

Norman-Taylor FH, Palmer CR, Villar RN. Quality-of-life improvement compared after hip and knee replacement. J Bone Joint Surg Br Vol. 1996;78(1):74.CrossRef

Martinez-Cano JP, Herrera-Escobar JP, Arango Gutierrez AS, Sanchez Vergel A, Martinez-Rondanelli A. Prospective quality of life assessment after hip and knee arthroplasty: short- and mid-term follow-up results. Arthroplast Today. 2017;3(2):125.CrossRefPubMed

Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint infection. Lancet (Lond Engl). 2016;387(10016):386.CrossRef

Berend KR, Lombardi AV Jr, Morris MJ, Bergeson AG, Adams JB, Sneller MA. Two-stage treatment of hip periprosthetic joint infection is associated with a high rate of infection control but high mortality. Clin Orthop Relat Res. 2013;471(2):510.CrossRefPubMed

Lamagni T. Epidemiology and burden of prosthetic joint infections. J Antimicrob Chemother. 2014;69(Suppl 1):i5.CrossRefPubMed

Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplast. 2012;27(8 Suppl):61.CrossRef

Alp E, Cevahir F, Ersoy S, Guney A. Incidence and economic burden of prosthetic joint infections in a university hospital: a report from a middle-income country. J Infect Public Health. 2016;9(4):494.CrossRefPubMed

Ciofu O, Rojo-Molinero E, Macia MD, Oliver A. Antibiotic treatment of biofilm infections. APMIS: Acta Pathol Microbiol Immunol Scand. 2017;125(4):304.CrossRef

Marculescu C, Berbari E, Hanssen AD, Steckelberg J, Harmsen S, Mandrekar J, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis. 2006;42(4):471.CrossRefPubMed

10.

Urish KL, Bullock AG, Kreger AM, Shah NB, Jeong K, Rothenberger SD. A multicenter study of irrigation and debridement in total knee arthroplasty periprosthetic joint infection: treatment failure is high. J Arthroplast. 2018;33(4):1154.CrossRef

11.

Klement MR, Siddiqi A, Rock JM, Chen AF, Bolognesi MP, Seyler TM. Positive blood cultures in periprosthetic joint infection decrease rate of treatment success. J Arthroplast. 2018;33(1):200.CrossRef

12.

Yoon HK, Cho SH, Lee DY, Kang BH, Lee SH, Moon DG, et al. Review of the literature on culture-negative periprosthetic joint infection: epidemiology, diagnosis and treatment. Knee Surg Relat Res. 2017;29(3):155.CrossRefPubMedPubMedCentral

13.

Wang J, Wang Q, Shen H, Zhang X. Comparable outcome of culture-negative and culture-positive periprosthetic hip joint infection for patients undergoing two-stage revision. Int Orthop. 2018;42(3):469.CrossRefPubMed

14.

Dibartola AC, Swearingen MC, Granger JF, Stoodley P, Dusane DH. Biofilms in orthopedic infections: a review of laboratory methods. APMI: Acta Pathol Microbiol Immunol Scand. 2017;125(4):418.CrossRef

15.

•• Swearingen MC, DiBartola AC, Dusane D, Granger J, Stoodley P. 16S rRNA analysis provides evidence of biofilms on all components of three infected periprosthetic knees including permanent braided suture. Pathog Dis 2016;74(7). This paper compared conventional bacterial culture techniques to 16S rRNA analysis of samples taken from patients undergoing revision knee replacement for infection. 16S sequencing identified multiple bacteria types on implant and suture material surfaces, demonstrating that the prevalence of polymicrobial infection is underestimated and that biofilm can form on all foreign materials inside the patient.

16.

Huang Z, Wu Q, Fang X, Li W, Zhang C, Zeng H, Wang Q, Lin J, Zhang W. Comparison of culture and broad-range polymerase chain reaction methods for diagnosing periprosthetic joint infection: analysis of joint fluid, periprosthetic tissue, and sonicated fluid. Int Orthop. 2018.

17.

Rothenberg AC, Wilson AE, Hayes JP, O'Malley MJ, Klatt BA. Sonication of arthroplasty implants improves accuracy of periprosthetic joint infection cultures. Clin Orthop Relat Res. 1827;475(7):2017.

18.

Tani S, Lepetsos P, Stylianakis A, Vlamis J, Birbas K, Kaklamanos I. Superiority of the sonication method against conventional periprosthetic tissue cultures for diagnosis of prosthetic joint infections. Eur J Orthop Surg Traumatol. 2018;28(1):51.CrossRefPubMed

19.

Janz V, Trampuz A, Perka CF, Wassilew GI. Reduced culture time and improved isolation rate through culture of sonicate fluid in blood culture bottles. Technol Health Care. 2017;25(4):635.CrossRefPubMed

20.

Clauss M. CORR insights((R)): sonication of arthroplasty implants improves accuracy of periprosthetic joint infection cultures. Clin Orthop Relat Res. 1837;475(7):2017.

21.

Wilson PD Jr, Salvati EA, Blumenfeld EL. The problem of infection in total prosthetic arthroplasty of the hip. Surg Clin North Am. 1975;55(6):1431.CrossRefPubMed

22.

Anagnostakos K, Wilmes P, Schmitt E, Kelm J. Elution of gentamicin and vancomycin from polymethylmethacrylate beads and hip spacers in vivo. Acta Orthop. 2009;80(2):193.CrossRefPubMedPubMedCentral

23.

Bertazzoni Minelli E, Benini A, Samaila E, Bondi M, Magnan B. Antimicrobial activity of gentamicin and vancomycin combination in joint fluids after antibiotic-loaded cement spacer implantation in two-stage revision surgery. J Chemother (Florence, Italy). 2015;27(1):17.CrossRef

24.

Edelstein AI, Okroj KT, Rogers T, Della Valle CJ, Sporer SM. Nephrotoxicity after the treatment of periprosthetic joint infection with antibiotic-loaded cement spacers. J Arthroplasty. 2018.

25.

Berliner ZP, Mo AZ, Porter DA, Grossman JM, Hepinstall MS, Cooper HJ, et al. In-hospital acute kidney injury after TKA revision with placement of an antibiotic cement spacer. J Arthroplast. 2017;

26.

Nelson CL, Jones RB, Wingert NC, Foltzer M, Bowen TR. Sonication of antibiotic spacers predicts failure during two-stage revision for prosthetic knee and hip infections. Clin Orthop Relat Res. 2014;472(7):2208.CrossRefPubMedPubMedCentral

27.

Schmolders J, Hischebeth GT, Friedrich MJ, Randau TM, Wimmer MD, Kohlhof H, et al. Evidence of MRSE on a gentamicin and vancomycin impregnated polymethyl-methacrylate (PMMA) bone cement spacer after two-stage exchange arthroplasty due to periprosthetic joint infection of the knee. BMC Infect Dis. 2014;14:144.CrossRefPubMedPubMedCentral

28.

Anagnostakos K, Furst O, Kelm J. Antibiotic-impregnated PMMA hip spacers: current status. Acta Orthop. 2006;77(4):628.CrossRefPubMed

29.

Erivan R, Lecointe T, Villatte G, Mulliez A, Descamps S, Boisgard S. Complications with cement spacers in 2-stage treatment of periprosthetic joint infection on total hip replacement. Orthop Traumatol Surg Res: OTSR. 2017.

30.

Armstrong MD, Carli AV, Abdelbary H, Poitras S, Lapner P, Beaule PE. Tertiary care centre adherence to unified guidelines for management of periprosthetic joint infections: a gap analysis. Can J Surg Journal canadien de chirurgie. 2018;61(1):34.CrossRefPubMed

31.

Ruder JA, Springer BD. Treatment of periprosthetic joint infection using antimicrobials: dilute povidone-iodine lavage. J Bone Joint Infect. 2017;2(1):10.CrossRef

32.

Frisch NB, Kadri OM, Tenbrunsel T, Abdul-Hak A, Qatu M, Davis JJ. Intraoperative chlorhexidine irrigation to prevent infection in total hip and knee arthroplasty. Arthroplast Today. 2017;3(4):294.CrossRefPubMedPubMedCentral

33.

Riesgo AM, Park BK, Herrero CP, Yu S, Schwarzkopf R, Iorio R. Vancomycin povidone-iodine protocol improves survivorship of periprosthetic joint infection treated with irrigation and debridement. J Arthroplast. 2018;33(3):847.CrossRef

34.

Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant–related staphylococcal infections: a randomized controlled trial. JAMA. 1998;279(19):1537.CrossRefPubMed

35.

O'Reilly T, Kunz S, Sande E, Zak O, Sande M, Täuber MG. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. Antimicrob Agents Chemother. 1992;36(12):2693.CrossRefPubMedPubMedCentral

36.

Keating GM, Scott LJ. Moxifloxacin. Drugs. 2004;64(20):2347.CrossRefPubMed

37.

Joukhadar C, Stass H, Müller-Zellenberg U, Lackner E, Kovar F, Minar E, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother. 2003;47(10):3099.CrossRefPubMedPubMedCentral

38.

Greimel F, Scheuerer C, Gessner A, Simon M, Kalteis T, Grifka J, et al. Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study. Drug Des Devel Ther. 2017;11:1729.CrossRefPubMedPubMedCentral

39.

Koziel J, Maciag-Gudowska A, Mikolajczyk T, Bzowska M, Sturdevant DE, Whitney AR, et al. Phagocytosis of Staphylococcus aureus by macrophages exerts cytoprotective effects manifested by the upregulation of antiapoptotic factors. PLoS One. 2009;4(4):e5210.CrossRefPubMedPubMedCentral

40.

Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527(7578):323.CrossRefPubMed

41.

Surewaard BG, Deniset JF, Zemp FJ, Amrein M, Otto M, Conly J, Omri A, Yates RM, Kubes P. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med : JEM. 2016 20160334.

42.

•• Zaidi S, Misba L, Khan AU. Nano-therapeutics: a revolution in infection control in post antibiotic era. Nanomedicine. 2017;13(7):2281. This paper provides an up to date, thorough overview of the possible applications of nano-therapeutics for infectious disease, summarizing advantages and limitations of nanoparticle-based platforms. CrossRefPubMed

43.

Liu Y, Busscher HJ, Zhao B, Li Y, Zhang Z, van der Mei HC, et al. Surface-adaptive, antimicrobially loaded, micellar nanocarriers with enhanced penetration and killing efficiency in staphylococcal biofilms. ACS Nano. 2016;10(4):4779.CrossRefPubMed

44.

Bazzaz BSF, Khameneh B, Zarei H, Golmohammadzadeh S. Antibacterial efficacy of rifampin loaded solid lipid nanoparticles against Staphylococcus epidermidis biofilm. Microb Pathog. 2016;93:137.CrossRef

45.

Chetoni P, Burgalassi S, Monti D, Tampucci S, Tullio V, Cuffini AM, et al. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: pharmacokinetic studies on rabbits. Eur J Pharm Biopharm. 2016;109:214.CrossRefPubMed

46.

Hippler R, Kersten H, Schmidt M, Schoenbach KH. Low temperature plasmas: fundamentals, technologies and techniques: Wiley-VCH. 2008.

47.

Moisan M, Barbeau J, Moreau S, Pelletier J, Tabrizian M, Yahia LH. Low-temperature sterilization using gas plasmas: a review of the experiments and an analysis of the inactivation mechanisms. Int J Pharm. 2001;226(1–2):1.CrossRefPubMed

48.

Moreau M, Orange N, Feuilloley M. Non-thermal plasma technologies: new tools for bio-decontamination. Biotechnol Adv. 2008;26(6):610.CrossRefPubMed

49.

Laroussi M, Lu X, Keidar M. Perspective: the physics, diagnostics, and applications of atmospheric pressure low temperature plasma sources used in plasma medicine. J Appl Phys. 2017;122(2):020901.CrossRef

50.

Ermolaeva SA, Varfolomeev AF, Chernukha MY, Yurov DS, Vasiliev MM, Kaminskaya AA, et al. Bactericidal effects of non-thermal argon plasma in vitro, in biofilms and in the animal model of infected wounds. J Med Microbiol. 2011;60(Pt 1):75.CrossRefPubMed

51.

Taha M, Kalab M, Yi QL, Landry C, Greco-Stewart V, Brassinga AK, et al. Biofilm-forming skin microflora bacteria are resistant to the bactericidal action of disinfectants used during blood donation. Transfusion. 2014;54(11):2974.CrossRefPubMed

52.

Horner C, Mawer D, Wilcox M. Reduced susceptibility to chlorhexidine in staphylococci: is it increasing and does it matter? J Antimicrob Chemother. 2012;67(11):2547.CrossRefPubMed

53.

Gupta TT, Karki SB, Matson JS, Gehling DJ, Ayan H. Sterilization of biofilm on a titanium surface using a combination of nonthermal plasma and chlorhexidine digluconate. Biomed Res Int. 2017;2017:6085741.PubMedPubMedCentral

54.

Brade KD, Rybak JM, Rybak MJ. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections. Infect Dis Ther. 2016;5(1):1.CrossRefPubMedPubMedCentral

55.

Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54(suppl_3):S214.CrossRefPubMed

56.

Lehoux D, Ostiguy V, Cadieux C, Malouin M, Belanger O, Far AR, et al. Oritavancin pharmacokinetics and bone penetration in rabbits. Antimicrob Agents Chemother. 2015;59(10):6501.CrossRefPubMedPubMedCentral

57.

Crotty MP, Krekel T, Burnham C-AD, Ritchie DJ. New gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides. J Clin Microbiol 54(9): 2225, 2016.

58.

Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother 59(4): 1849, 2015.

59.

Fernández J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis. 2016;85(4):449.CrossRefPubMed

60.

Barnea Y, Lerner A, Aizic A, Navon-Venezia S, Rachi E, Dunne MW, et al. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. J Antimicrob Chemother. 2015;71(2):460.CrossRefPubMed

61.

Yang Y, Qian M, Yi S, Liu S, Li B, Yu R, et al. Monoclonal antibody targeting staphylococcus aureus surface protein A (SasA) protect against staphylococcus aureus sepsis and peritonitis in mice. PLoS One. 2016;11(2):e0149460.CrossRefPubMedPubMedCentral

62.

Varshney AK, Kuzmicheva GA, Lin J, Sunley KM, Bowling RA Jr, Kwan T-Y, et al. A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018;13(1):e0190537.CrossRefPubMedPubMedCentral

63.

Li YJ, Harroun SG, Su YC, Huang CF, Unnikrishnan B, Lin HJ, et al. Synthesis of self-assembled spermidine-carbon quantum dots effective against multidrug-resistant bacteria. Adv Healthcare Mater. 2016;5(19):2545.CrossRef

64.

Qayyum S, Khan AU. Biofabrication of broad range antibacterial and antibiofilm silver nanoparticles. IET Nanobiotechnol. 2016;10(5):349.CrossRefPubMed

65.

Kulshrestha S, Qayyum S, Khan AU. Antibiofilm efficacy of green synthesized graphene oxide-silver nanocomposite using Lagerstroemia speciosa floral extract: a comparative study on inhibition of gram-positive and gram-negative biofilms. Microb Pathog. 2017;103:167.CrossRefPubMed

66.

Bahar AA, Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6(12):1543.CrossRefPubMedPubMedCentral

67.

Zhao X, Wu H, Lu H, Li G, Huang QLAMP, A Database. Linking antimicrobial peptides. PLoS One. 2013;8(6):e66557.CrossRefPubMedPubMedCentral

68.

Gao Y, Wu D, Wang L, Lin C, Ma C, Xi X, et al. Targeted modification of a novel amphibian antimicrobial peptide from Phyllomedusa tarsius to enhance its activity against MRSA and microbial biofilm. Front Microbiol. 2017;8:628.PubMedPubMedCentral

69.

Shin JM, Ateia I, Paulus JR, Liu H, Fenno JC, Rickard AH, et al. Antimicrobial nisin acts against saliva derived multi-species biofilms without cytotoxicity to human oral cells. Front Microbiol. 2015;6:617.CrossRefPubMedPubMedCentral

70.

Zapotoczna M, Forde É, Hogan S, Humphreys H, O’gara JP, Fitzgerald-Hughes D, Devocelle M, O’neill E. Eradication of Staphylococcus aureus biofilm infections using synthetic antimicrobial peptides. J Infect Dis 215(6): 975, 2017.

71.

de la Fuente-Núñez C, Reffuveille F, Mansour SC, Reckseidler-Zenteno SL, Hernández D, Brackman G, et al. D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem Biol. 2015;22(2):196.CrossRefPubMedPubMedCentral

72.

Mansour SC, Pletzer D, de la Fuente-Nunez C, Kim P, GYC C, Joo HS, et al. Bacterial abscess formation is controlled by the stringent stress response and can be targeted therapeutically. EBioMedicine. 2016;12:219.CrossRefPubMedPubMedCentral

73.

de Breij A, Riool M, Cordfunke RA, Malanovic N, de Boer L, Koning RI, et al. The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci Transl Med. 2018;10(423):eaan4044.CrossRefPubMed

74.

Salmond GP, Fineran PC. A century of the phage: past, present and future. Nat Rev Microbiol. 2015;13(12):777.CrossRefPubMed

75.

•• Gutiérrez D, Rodríguez-Rubio L, Martínez B, Rodríguez A, García P. Bacteriophages as weapons against bacterial biofilms in the food industry. Front Microbiol. 2016;7:825. This paper demonstrates the capability of bacteriophages in clearing established biofilms on food surfaces. The described experiment performs successful against clinically relevant bacterial strains and has indirect application to periprosthetic joint infection research. CrossRefPubMedPubMedCentral

76.

Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954.CrossRefPubMedPubMedCentral

77.

Akanda ZZ, Taha M, Abdelbary H. Current review—the rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections. J Orthop Res, 2017.

78.

Alves DR, Perez-Esteban P, Kot W, Bean J, Arnot T, Hansen LH, Enright MC, Jenkins ATA. A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa biofilms under static and flow conditions. Microb Biotechnol 9(1): 61, 2016.

79.

Kumaran D, Taha M, Yi Q, Ramirez S, Diallo J-S, Carli A, et al. Does treatment order matter? Investigating the ability of bacteriophage to augment antibiotic activity against Staphylococcus aureus biofilms. Front Microbiol. 2018;9:127.CrossRefPubMedPubMedCentral

80.

Chaudhry WN, Concepción-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR. Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One. 2017;12(1):e0168615.CrossRefPubMedPubMedCentral

81.

Kishor C, Mishra RR, Saraf SK, Kumar M, Srivastav AK, Nath G. Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J Med Res. 2016;143(1):87.CrossRefPubMedPubMedCentral

82.

Breyne K, Honaker RW, Hobbs Z, Richter M, Żaczek M, Spangler T, et al. Safety of a bovine-associated Staphylococcus aureus phage cocktail in a murine model of mastitis. Front Microbiol. 2017;8

83.

Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagn Photodyn Ther. 2005;2(1):1.CrossRef

84.

•• Briggs T, Blunn G, Hislop S, Ramalhete R, Bagley C, McKenna D, Coathup M. Antimicrobial photodynamic therapy—a promising treatment for prosthetic joint infections. Lasers Med Sci. 2017;1. This paper involved a thorough evaluation of the photodynamic therapy (PDT) on the biofilms of four distinct clinical isolates of bacteria found in clinical periprosthetic joint infection. The study found that staphylococcus bacteria could be effectively removed using PDT in tested conditions/.

85.

Giannelli M, Landini G, Materassi F, Chellini F, Antonelli A, Tani A, et al. Effects of photodynamic laser and violet-blue led irradiation on Staphylococcus aureus biofilm and Escherichia coli lipopolysaccharide attached to moderately rough titanium surface: in vitro study. Lasers Med Sci. 2017;32(4):857.CrossRefPubMed

86.

Ehrensberger MT, Tobias ME, Nodzo SR, Hansen LA, Luke-Marshall NR, Cole RF, et al. Cathodic voltage-controlled electrical stimulation of titanium implants as treatment for methicillin-resistant Staphylococcus aureus periprosthetic infections. Biomaterials. 2015;41:97.CrossRefPubMed

87.

•• Nodzo SR, Tobias M, Ahn R, Hansen L, Luke-Marshall NR, Howard C, et al. Cathodic voltage-controlled electrical stimulation plus prolonged vancomycin reduce bacterial burden of a titanium implant-associated infection in a rodent model. Clin Orthop Relat Res. 2016;474(7):1668. This paper provides a clinically representative rodent model of shoulder periprosthetic joint infection, demonstrating the effectiveness of electrical stimulation combined with vancomycin in clearing infection on a shoulder implant with established biofilm. CrossRefPubMedPubMedCentral

Title: New Innovations in the Treatment of PJI and Biofilms—Clinical and Preclinical Topics
Authors: Mariam Taha
Hesham Abdelbary
F. Patrick Ross
Alberto V. Carli
Publication date: 01-09-2018
Publisher: Springer US
Published in: Current Reviews in Musculoskeletal Medicine / Issue 3/2018
Electronic ISSN: 1935-9748
DOI: https://doi.org/10.1007/s12178-018-9500-5

ACC 2024 Congress

Springer Medicine

New Innovations in the Treatment of PJI and Biofilms—Clinical and Preclinical Topics

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Retrograde Hindfoot Nailing for Acute Trauma

Perioperative and Modifiable Risk Factors for Periprosthetic Joint Infections (PJI) and Recommended Guidelines

The Role of One-Stage Exchange for Prosthetic Joint Infection

Staphylococcus aureus Evasion of Host Immunity in the Setting of Prosthetic Joint Infection: Biofilm and Beyond

Limited Approaches to Calcaneal Fractures

Indications and Guidelines for Debridement and Implant Retention for Periprosthetic Hip and Knee Infection